Promethera is a biotechnology company focused on developing advanced cell-based therapies for the treatment of severe liver diseases. The company primarily serves patients suffering from acute on chronic liver failure (ACLF) and other end-stage liver diseases. Operating in the regenerative medicine market, Promethera leverages its proprietary technology and intellectual property to create innovative treatments aimed at restoring liver health and reducing the need for liver transplants. The company's flagship product, HepaStem, is a stem cell-based therapy designed to act as a medicinal signaling cargo to the diseased liver, promoting regeneration and healing. Promethera generates revenue through the development and commercialization of its therapeutic products, targeting healthcare providers and patients in urgent need of liver transplantation. The business model is centered around research and development, clinical trials, and partnerships with healthcare institutions to bring its therapies to market. Promethera's unique technological assets and exclusive intellectual property position it as a leader in the field of liver regenerative medicine.

Keywords: liver diseases, cell-based therapies, regenerative medicine, HepaStem, ACLF, liver transplantation, biotechnology, intellectual property, healthcare, innovation.